IASO Pharma Inc Stock

IASO Pharma Inc., formerly Pacific Beach BioSciences, Inc., is a biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment and prevention of infectious diseases. The Company has obtained rights to candidates for the treatment of bacterial and fungal infections. During the year ended December 31, 2009, the Company licensed all of the products in its pipeline. Its product candidates focus to address market opportunities in the antibiotic and antifungal markets, including its advanced product candidate, PB-101 (zabofloxacin). PB-101 is a fluoroquinolone antibiotic, it plans to develop for the treatment of community-acquired pneumonia (CAP). In the antifungal market, it is focused on developing PB-200a, a drug candidate, and PB-201, a technology that may result in one or more additional drug candidates.